Kite’s CAR-T Therapy Makes It Back Onto EMA’s PRIME, Along With Three New Products

 
• By Neena Brizmohun
  
3d illustration of T cells or cancer cells
Kite's CAR-T therapy is among the four new products accepted onto the PRIME scheme
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Market Access

More from Pink Sheet